Serafin, A., Angotzi, F., Bevilacqua, A., Cellini, A., D’antiga, M., Bonaldi, L., Martines, A., Albi, E., Sant’antonio, E., Martini, F., De Antoni, S., Pepe, S., Cavallari, I., Noto, A., Frustaci, A., Mauro, F., Ghia, P., Scarfò, L., Trentin, L. and Visentin, A. (2026) “P065 | Clinical and genomic patterns of disease progression in CLL patients treated with fixed-duration versus continuous targeted therapies: A. Serafin1, F. Angotzi1, A. Bevilacqua1, A. Cellini1, M. D’antiga1, L. Bonaldi2, A. Martines2, E. Albi3, E. Sant’antonio3, F. Martini3, S. De Antoni2, S. Pepe4, I. Cavallari2, A. Noto5, A.M. Frustaci5, F.R. Mauro4, P. Ghia3|6, L. Scarfò3|6, L. Trentin1, A. Visentin1 | 1Hematology Unit, Department of Medicine, University of Padova; 2Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS; 3Strategic Research Program on CLL, IRCCS Ospedale San Raffaele; 4Hematology, Department of Translational and Precision Medicine, "Sapienza" University; 5Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda; 6Medical School, Università Vita-Salute San Raffaele”, Haematologica. Pavia, Italy, 111(s1). doi: 10.3324/haematol.2026.s1.130.